"Seeing the World" is a project aimed at reducing visual impairment caused by retinopathy in premature newborns. The AYALA Charitable Foundation is raising funds for the medication "Lucentis" to treat aggressive forms of retinopathy in newborns at the regional children's clinical hospital in the Karaganda region, as well as in the regional clinical hospital in the Karaganda region.
The danger of retinopathy in premature infants is that there are no external signs of the disease. Only a specialized ophthalmologist using special equipment can detect early signs of this disease within 21 days of the child's birth and refer them for treatment. The earlier the child is born, the more severe the retinopathy is. In Kazakhstan, aggressive forms of retinopathy in premature infants are prevalent due to a number of unfavorable environmental factors.
In order to reduce the incidence of retinopathy since 2022, the Foundation has provided 5 laser systems, 6 retinal cameras, 14 ophthalmoscopes, and 84 vials of the drug "Lucentis" to state scientific and perinatal centers in Kazakhstan. This has helped increase the coverage of newborns with ophthalmological screening in Kazakhstan by 11.8%, increase the detection rate of retinopathy in premature infants by 20.6%, and perform 34.3% more retinal laser coagulation surgeries.
Currently, in Kazakhstan, the medicine "Lucentis" (active ingredient - ranibizumab) is approved for use as an angiogenesis inhibitor in the treatment of retinopathy in premature newborns. The use of the drug "Lucentis" has a long-term effect: it helps in the development of retinal blood vessels in premature newborns and is used prior to retinal laser coagulation in aggressive forms of retinopathy. The "Lucentis" drug will help save hundreds of children from visual disability and see the world!
Support this important cause by creating a personalized fundraising page.
Start a Fundraiser
